Synergistic bacterial compositions and methods of production and use thereof
Inventors
Henn, Matthew R. • Litcofsky, Kevin Daniel • D'Onofrio, Anthony Mario • Ohsumi, Toshiro K. • McKenzie, Mary-Jane Lombardo • von Maltzahn, Geoffrey • Cook, David N. • Berry, David Arthur • Afeyan, Noubar B. • Aunins, John Grant
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
Core Innovation
The composition comprises a therapeutically effective amount of a population of bacterial spores, including isolated Clostridium disporicum, Blautia producta, and Coprococcus comes spores. Each spore type comprises a 16S nucleic acid sequence at least 97% identical to the corresponding sequence identified in the claim. The population synergistically decreases or inhibits the growth or colonization of at least one species of pathogenic bacteria in the human gastrointestinal tract.
The screening result details bacterial combinations and compositions that restore or populate the gastrointestinal microbiome through microbial engraftment or augmentation. The compositions exhibit inhibitory activity against pathogens including Clostridium difficile, vancomycin-resistant Enterococcus, Klebsiella pneumoniae, and Morganella morganii. Selected spore compositions protect in murine infection models, improve relapse survival, resolve associated disease, reduce pathobionts, and increase microbiome diversity.
Claims Coverage
The provided claims identify one independent claim comprising inventive features directed to a defined bacterial-spore composition and its synergistic pathogen-inhibiting activity.
Three-species bacterial-spore composition
The composition comprises a therapeutically effective amount of a population of bacterial spores, including at least one isolated Clostridium disporicum spore, at least one isolated Blautia producta spore, and at least one isolated Coprococcus comes spore, each comprising a 16S nucleic acid sequence at least 97% identical to the respective sequence specified in the claim.
Synergistic inhibition of pathogenic bacteria
The population of bacterial spores synergistically decreases or inhibits the growth or colonization of at least one species of pathogenic bacteria in a human gastrointestinal tract, including synergistic inhibition of Clostridium difficile in a CivSim assay with a confidence interval greater than 99%.
Reduction of C. difficile abundance
The composition is administered to reduce Clostridium difficile abundance in a human subject's gastrointestinal tract.
The claim coverage centers on a therapeutically effective composition containing spores of three specified bacterial species, their sequence-identity criteria, and their synergistic activity to inhibit pathogenic bacteria and reduce C. difficile abundance.
Stated Advantages
The population of bacterial spores can synergistically decrease or inhibit the growth or colonization of pathogenic bacteria in the human gastrointestinal tract.
Treatment with the spore composition resolves C. difficile-associated disease, reduces pathobionts, and increases microbiome diversity.
Documented Applications
Administration of the composition to reduce Clostridium difficile abundance in a human subject's gastrointestinal tract and to treat C. difficile-associated disease, including recurrent disease.
Restoration or population of the gastrointestinal microbiome through microbial engraftment or augmentation.
Inhibition of pathogenic bacterial species including Clostridium difficile, vancomycin-resistant Enterococcus (VRE), Klebsiella pneumoniae, and Morganella morganii, and evaluation of relapse survival in combination with vancomycin.
Interested in licensing this patent?